Skip to main content

Table 1 Baseline characteristics (n = 17)

From: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Baseline characteristics n (% or range)
Age 66 (45–79)
Baseline PSA (ng/mL) 79.7 (3.9–2356)
Baseline Hemoglobin (g/dL) 12.2 (9.3–14.5)
Baseline LDH (U/L) 241 (153–351)
Baseline Alkaline Phosphatase (U/L) 80 (56–643)
Baseline CTCs (in 10 mL blood) 12 (0–2107)
Prior treatment with:
 Enzalutamide 16 (94%)
 Abiraterone 11 (65%)
 Both 10 (59%)
 Prior immunotherapy 8 (47%)
 Prior chemotherapy 11 (65%)
Gleason score
 <  8 5 (29%)
 8–10 12 (71%)
ECOG performance status
 0 2 (12%)
 1 14 (82%)
 2 1 (6%)
Disease site:
 Bone only 5 (29%)
 Bone/soft tissue/viscera 12 (71%)